WO2002003910A2 - Preparation antibacterienne, anticancerigene, antioxydante et immunomodulatrice et procede d'utilisation - Google Patents

Preparation antibacterienne, anticancerigene, antioxydante et immunomodulatrice et procede d'utilisation Download PDF

Info

Publication number
WO2002003910A2
WO2002003910A2 PCT/RU2001/000276 RU0100276W WO0203910A2 WO 2002003910 A2 WO2002003910 A2 WO 2002003910A2 RU 0100276 W RU0100276 W RU 0100276W WO 0203910 A2 WO0203910 A2 WO 0203910A2
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
days
different
fact
προφilaκτiκi
Prior art date
Application number
PCT/RU2001/000276
Other languages
English (en)
Russian (ru)
Other versions
WO2002003910A3 (fr
Inventor
Raisa Ivanovna Yakubovskaya
Anna Vladimirovna Boyko
Elena Romanovna Nemtsova
Nadezhda Anatolievna Osipova
Tatyana Vladimirovna Sergeeva
Valery Ivanovich Chissov
Original Assignee
Raisa Ivanovna Yakubovskaya
Anna Vladimirovna Boyko
Elena Romanovna Nemtsova
Nadezhda Anatolievna Osipova
Tatyana Vladimirovna Sergeeva
Valery Ivanovich Chissov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raisa Ivanovna Yakubovskaya, Anna Vladimirovna Boyko, Elena Romanovna Nemtsova, Nadezhda Anatolievna Osipova, Tatyana Vladimirovna Sergeeva, Valery Ivanovich Chissov filed Critical Raisa Ivanovna Yakubovskaya
Priority to AU2001277824A priority Critical patent/AU2001277824A1/en
Publication of WO2002003910A2 publication Critical patent/WO2002003910A2/fr
Publication of WO2002003910A3 publication Critical patent/WO2002003910A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the group of inventions is related to the medicines containing the drugs, and the name of the person is the medicine and the methods of use thereof.
  • a well-known product is made in the form of yellowing meds, containing a lactosephalic mother in a quantity of 6 mg of breastmilk for a blueberry.
  • the drug which is taken for the simple remedy, is missing: a special case of the used medicinal form; restrictions on the ways of introducing drugs into an organism; Limitations to the indications of the use of the preparation.
  • usl ⁇ viya is ⁇ lz ⁇ vaniya in lechebn ⁇ m ⁇ tsesse la ⁇ e ⁇ ina ⁇ vy in ⁇ v ⁇ emya, ⁇ a ⁇ izves ⁇ n ⁇ ; "ch ⁇ la ⁇ e ⁇ in ⁇ vy yavlyae ⁇ sya immun ⁇ gennym for chel ⁇ ve ⁇ a and eg ⁇ vnu ⁇ ivenn ⁇ e, vnu ⁇ i ⁇ l ⁇ s ⁇ n ⁇ e, ⁇ d ⁇ zhn ⁇ e, vnu ⁇ imyshechn ⁇ e ⁇ imenenie 15 nev ⁇ zm ⁇ zhn ⁇ , ⁇ a ⁇ ⁇ a ⁇ even niz ⁇ i ⁇ d ⁇ za ⁇ ⁇ n ⁇ m ⁇ zhe ⁇ vyzva ⁇ alle ⁇ giches ⁇ y sh ⁇ .
  • the drug is used in the form of a liquid preparation, a drug is in use, or is in possession of an addictive ⁇ ⁇ ichinam, ⁇ e ⁇ ya ⁇ s ⁇ vuyuschim d ⁇ s ⁇ izheniyu ⁇ isann ⁇ g ⁇ below lechebn ⁇ g ⁇ e ⁇ e ⁇ a ⁇ i is ⁇ lz ⁇ vanii izves ⁇ n ⁇ g ⁇ ⁇ e ⁇ a ⁇ a, ⁇ n ⁇ si ⁇ sya ⁇ g ⁇ anichenn ⁇ s ⁇ ⁇ blas ⁇ i ⁇ imeneniya treatment in ⁇ e ⁇ tsi ⁇ nny ⁇ zab ⁇ levany 25 vyzvanny ⁇ ⁇ edelennym vid ⁇ m ⁇ a ⁇ genny ⁇ mi ⁇ ganizm ⁇ v
  • the claimed group of inventions is aimed at solving a single task -
  • active material 0.2 - 1.0% benefits for a direct or intravaginal application with a concentration of the main active substance 0.2 - 1.0%; Tablets with the contents of the main active substance 1 - 5%.
  • the inventive drug contains, as part of the main active substance, the human substance known to its antibacterial, antioxidant, and antioxidants.
  • a human person may be isolated from a female person and another biological person, and also obtained by genetic engineering or transgenic methods.
  • ⁇ sn ⁇ vnym susches ⁇ vennym ⁇ lichiem zayavlyaem ⁇ g ⁇ ⁇ e ⁇ a ⁇ a ⁇ a ⁇ vse ⁇ ⁇ anee izves ⁇ ny ⁇ le ⁇ a ⁇ s ⁇ venny ⁇ s ⁇ eds ⁇ v, s ⁇ de ⁇ zhaschi ⁇ la ⁇ e ⁇ in, yavlyae ⁇ sya ⁇ , ch ⁇ 0 ⁇ n ⁇ eds ⁇ avlyae ⁇ s ⁇ b ⁇ y ⁇ ntsen ⁇ a ⁇ in ⁇ me ⁇ sh ⁇ a, s ⁇ vmes ⁇ imy any ⁇ a ⁇ matsev ⁇ iches ⁇ i ⁇ ig ⁇ dnymi n ⁇ si ⁇ elyami.
  • the claimed 5 terms of concentration of lactose in the drug make it possible to keep the lactose in the native state, i.e. in the state of maximum physiological activity.
  • the product is the original product for the use of the drugs listed above. ⁇ liches ⁇ v ⁇ la ⁇ e ⁇ ina in ⁇ azlichny ⁇ ⁇ a ⁇ matsev ⁇ iches ⁇ i ⁇ igodny ⁇ n ⁇ si ⁇ elya ⁇ s ⁇ g ⁇ 0 de ⁇ e ⁇ mini ⁇ van ⁇ in ⁇ azhd ⁇ y le ⁇ a ⁇ s ⁇ venn ⁇ y ⁇ me in zavisim ⁇ s ⁇ i ⁇ ne ⁇ b ⁇ dim ⁇ s ⁇ i s ⁇ aneniya gli ⁇ eida in ⁇ izi ⁇ l ⁇ giches ⁇ i a ⁇ ivn ⁇ y ⁇ me and ⁇ a ⁇ zhe ⁇ tseles ⁇ b ⁇ azn ⁇ s ⁇ i administration le ⁇ a ⁇ s ⁇ vennuyu ⁇ mu ⁇ edelen
  • the inventive drug as well as medicinal products manufactured on its basis, underwent clinical trials.
  • the high therapeutic efficacy of the drug test ifies to the following clinical examples of its use. 1. An introductory introduction.
  • the drug was administered internally before a radiation treatment. After the 3rd injection (a single dose of 50 mg, a dry dose of 150 mg), there was a marked decrease in the manifestations of acute toxicity, a decrease in weakness, and a manifestation of the disease. The subsequent radiation treatment (in the case of a dynamic activity of the dose up to 32 Gp) without radiation reactions.
  • Bolny L. Diagnosis cancer of the third stage. Status after a curative treatment. ⁇ In the aftermath of a transient fecal incense, sepsis, miscarriages. . The hospital had an antibacterial and portable therapy without positive dynamics.
  • Diagn ⁇ z ⁇ a ⁇ leg ⁇ g ⁇ W s ⁇ adii, s ⁇ s ⁇ yanie ⁇ sle ⁇ i ⁇ u ⁇ giches ⁇ g ⁇ 'treatment. ⁇ after the process of empyema pleura, fistula. Biological analysis of the liquid from the pleural area: Zeziotostasis aegusidae, ⁇ founded ⁇ êt ⁇ ssessess eruscegtus. The drug was administered internally within 40 days after a day in a single dose of 25 mg. There was a marked disappearance of the antigen in the liquid from the pleural area on the 40th day of observation. Patient X.
  • Diagnosis urinary tract cancer II stage II: Condition after urinary tract resection, radiation therapy. Simple pyelone, cystit. Immediate administration of the drug in a daily dose of 25 mg daily for 10 days eliminated the manifestations of pyelonephritis, cystitis.
  • Patient B Diagnosis: lymphadenopathy at the stage of lymph nodes.
  • P ⁇ endoxan, vincristine, etoposide; 9 Recognition of a small share of opaque epithelium in the mucous area of the mouth. With the use of gelatinous diseases, containing the drug, the cleaning of the ulcerated area for 2 days, began the epithelization after 3 days.
  • An industrial appliance containing an appliance.
  • Diagnosis short-circuiting: severity of eyelids, tearing, luminescence, hyperemia, and swollen mucous membrane.
  • Patient S. Diagnosis a simpler inflammation of the obstructive nose. Complaints of sensation of pressure in the area of nasal sinus, headache, weak mucous discharge from the nose. The intranasal use of the product, which supports the preparation, has contributed to an increase in cervical septicemia and cleansing of the nose on the 7th day.
  • the inventive group of inventions complies with the requirements for equipment for novelty, inventories and industrial equipment.
  • the claimed group of inventions possesses other advantages in comparison with the ones used at the present time on the basis of medicinal products and means of communications.
  • the product is compatible with the human organism and the therapeutic 11 is highly effective, it is compatible with any pharmaceutical substances: disinfectants, ointments, gels;
  • the drug is suitable for the manufacture of medicinal products intended for the treatment of diseases of different localization; on the basis of the product, medicinal products can be prepared by any required concentration; the appliance is convenient in storage and distribution; medicinal products manufactured on a basic product may have been introduced into the body of a medical device by any of the known external arteries: use in clinical practice of medicinal products manufactured on the basis of a medication, is free to health; medicinal products on the basis of a medicine containing a human patient can be manufactured under the conditions of any clinic or medicine; The product is available at a price, its use in the medical treatment of economic treatment is given.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention relève de la médecine et concerne une préparation antibactérienne, anticancérigène, antioxydante et immunomodulatrice. Selon l'invention, la préparation comprend de la lactoferrine humaine, utilisée comme principe actif, et des additifs pharmaceutiquement acceptables; elle est destinée à la préparation de médicaments ou concerne des médicaments comprenant la préparation et des excipients pharmaceutiquement acceptables tels qu'une solution pour injection intraveineuse, une solution destinée à l'instillation endocavitaire ou intravésicale, une solution destinée à l'introduction pérorale, une solution destinée au traitement des surfaces des blessures, une solution pour introduction intranasale ou se présentant comme des gouttes oculaires, une pommade, des dragées à administration pérorale, des suppositoires à administration rectale ou intravaginale et des comprimés. L'invention concerne aussi un procédé de prévention et/ou de traitement des maladies au moyen de la préparation contenant de la lactoferrine humaine. L'invention permet de créer une préparation et des médicaments à base de cette préparation ayant un coût accessible.
PCT/RU2001/000276 2000-07-13 2001-07-09 Preparation antibacterienne, anticancerigene, antioxydante et immunomodulatrice et procede d'utilisation WO2002003910A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001277824A AU2001277824A1 (en) 2000-07-13 2001-07-09 Antibacterial, antioxidant, immunomoduling and anticancerogenic preparation and method for using said preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2000118424/14A RU2165769C1 (ru) 2000-07-13 2000-07-13 Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения
RU2000118424 2000-07-13

Publications (2)

Publication Number Publication Date
WO2002003910A2 true WO2002003910A2 (fr) 2002-01-17
WO2002003910A3 WO2002003910A3 (fr) 2002-06-20

Family

ID=20237690

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2001/000276 WO2002003910A2 (fr) 2000-07-13 2001-07-09 Preparation antibacterienne, anticancerigene, antioxydante et immunomodulatrice et procede d'utilisation

Country Status (3)

Country Link
AU (1) AU2001277824A1 (fr)
RU (1) RU2165769C1 (fr)
WO (1) WO2002003910A2 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034126B2 (en) 2003-05-14 2006-04-25 Agennix, Inc. Lactoferrin in the treatment of diabetes mellitus
US7183381B2 (en) 2004-10-26 2007-02-27 Agennix, Inc. Composition of lactoferrin related peptides and uses thereof
US7244706B2 (en) 1999-02-05 2007-07-17 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
US7323443B2 (en) 2002-12-12 2008-01-29 Agennix Inc. Lactoferrin in the reduction of pain
US7524814B2 (en) 2002-09-16 2009-04-28 Agennix, Inc. Lactoferrin compositions and methods of wound treatment
US7592306B2 (en) 2002-12-10 2009-09-22 Agennix, Inc. Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
US7901879B2 (en) 2002-05-10 2011-03-08 Agennix Incorporated Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
US8105615B2 (en) 2003-06-06 2012-01-31 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
US20140357550A1 (en) * 2012-02-16 2014-12-04 OOO "NTpharma" Pharmaceutical Composition for Treatment of Acute Toxic Conditions

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2643344B1 (fr) 2010-11-26 2017-03-22 Evonik Röhm GmbH Peptides basées sur la séquence de lactoferrin humain et leur utilisation comme agent de masquage d'un antigène
EP2481751A1 (fr) * 2011-01-26 2012-08-01 PharmaSurgics in Sweden AB Homme peptides dérivés de lactoferrine
RU2687969C1 (ru) * 2018-03-02 2019-05-17 Федеральное государственное бюджетное учреждение науки Институт биологии гена Российской академии наук Антимикробное средство

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543392A (en) * 1992-07-29 1996-08-06 Morinaga Milk Industry Co., Ltd. Digestive tract cell activating agent of EGF and lactoferrin
RU2099065C1 (ru) * 1994-09-23 1997-12-20 Московский научно-исследовательский онкологический институт им. П.А.Герцена МЗ РФ Препарат для лечения местных осложнений консервативного противоопухолевого лечения в орофарингеальной зоне и способ лечения осложнений консервативного противоопухолевого лечения в орофарингеальной зоне
WO1998044940A1 (fr) * 1997-04-10 1998-10-15 Agennix, Inc. Utilisation de la lactoferrine dans le traitement des troubles induits par allergenes
EP0955058A1 (fr) * 1997-01-09 1999-11-10 Morinaga Milk Industry Co., Ltd. Comprimes de lactoferrine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2088238C1 (ru) * 1995-02-28 1997-08-27 Московский научно-исследовательский онкологический институт им.П.А.Герцена Средство для лечения ревматоидных артритов

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543392A (en) * 1992-07-29 1996-08-06 Morinaga Milk Industry Co., Ltd. Digestive tract cell activating agent of EGF and lactoferrin
RU2099065C1 (ru) * 1994-09-23 1997-12-20 Московский научно-исследовательский онкологический институт им. П.А.Герцена МЗ РФ Препарат для лечения местных осложнений консервативного противоопухолевого лечения в орофарингеальной зоне и способ лечения осложнений консервативного противоопухолевого лечения в орофарингеальной зоне
EP0955058A1 (fr) * 1997-01-09 1999-11-10 Morinaga Milk Industry Co., Ltd. Comprimes de lactoferrine
WO1998044940A1 (fr) * 1997-04-10 1998-10-15 Agennix, Inc. Utilisation de la lactoferrine dans le traitement des troubles induits par allergenes

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244706B2 (en) 1999-02-05 2007-07-17 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
US7901879B2 (en) 2002-05-10 2011-03-08 Agennix Incorporated Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
US8242079B2 (en) 2002-05-10 2012-08-14 Agennix Incorporated Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
US8247373B2 (en) 2002-09-16 2012-08-21 Agennix Incorporated Lactoferrin compositions and methods of wound treatment
US8030272B2 (en) 2002-09-16 2011-10-04 Agennix Incorporated Lactoferrin compositions and methods of wound treatment
US7524814B2 (en) 2002-09-16 2009-04-28 Agennix, Inc. Lactoferrin compositions and methods of wound treatment
US7592306B2 (en) 2002-12-10 2009-09-22 Agennix, Inc. Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
US8058234B2 (en) 2002-12-10 2011-11-15 Agennix Incorporated Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
US7638487B2 (en) 2002-12-12 2009-12-29 Agennix, Inc. Lactoferrin in the reduction of pain
US7323443B2 (en) 2002-12-12 2008-01-29 Agennix Inc. Lactoferrin in the reduction of pain
US7034126B2 (en) 2003-05-14 2006-04-25 Agennix, Inc. Lactoferrin in the treatment of diabetes mellitus
US8105615B2 (en) 2003-06-06 2012-01-31 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
US7420033B2 (en) 2004-10-26 2008-09-02 Agennix, Inc. Composition of lactoferrin related peptides and uses thereof
US7183381B2 (en) 2004-10-26 2007-02-27 Agennix, Inc. Composition of lactoferrin related peptides and uses thereof
US20140357550A1 (en) * 2012-02-16 2014-12-04 OOO "NTpharma" Pharmaceutical Composition for Treatment of Acute Toxic Conditions

Also Published As

Publication number Publication date
RU2165769C1 (ru) 2001-04-27
AU2001277824A1 (en) 2002-01-21
WO2002003910A3 (fr) 2002-06-20

Similar Documents

Publication Publication Date Title
WO2002003910A2 (fr) Preparation antibacterienne, anticancerigene, antioxydante et immunomodulatrice et procede d'utilisation
NZ524076A (en) Preventing or treating diseases associated with allergies, autoimmunity and adhesion, metastatic and coronary cascades using complex carbohydrates, in particular hyaluronic acid
AU2001281368A1 (en) Methods of preventing or treating diseases and conditions using complex carbohydrates
RU2616520C2 (ru) Лечение симптомов, связанных с гастропарезом у женщин
RU2419449C1 (ru) Средство для лечения больных лекарственным гепатитом
US7879824B2 (en) Methods of preventing or treating diseases and conditions using complex carbohydrates
Bastedo Materia Medica
WO1993013764A1 (fr) Preparation pharmaceutique a action antistress, de prevention du stress et nootrope
WO1994028153A2 (fr) Adn de faible masse moleculaire tiree de laitance d'esturgeon, procede d'obtention de l'adn et preparation pharmaceutique a base de celui-ci
WO1989009607A1 (fr) Preparation bacterienne pour prophylaxie et traitement de processus inflammatoires et d'affections allergiques
Singh Pharmacology for dentistry
CN110101845B (zh) 鸢尾素在制备防治术后认知功能障碍以及血脑屏障受损所介导脑病的药物中的应用
CN111228247B (zh) 一种用于治疗包虫病的含苯亚甲基丙酮药物及其制备方法
CN110063989A (zh) 一种治疗食管癌的药物组合物及其制备方法
US4990513A (en) Antihypoxic drug and method of its application
CN102573861A (zh) 眼镜蛇神经毒素的口服制剂组成与方法
WO2002074311A1 (fr) Preparation medicinale antitumorale, antivirale, antibacterienne, antiparasitaire, anti-inflammatoire, antifongique et immunomodulatrice, procede de fabrication et formes de medicaments
SU1678375A1 (ru) Способ лечени иерсиниоза
Horoshko Influence of nano-drugs on lipid and protein peroxidation processes in experimental acute renal failure
RU2124897C1 (ru) Гомеопатическое лекарственное средство "антигриппин-аrn"
RU2438678C2 (ru) Способ лечения и профилактики узлового зоба
CN1117563C (zh) 一种消化系统癌病止痛药物组合物
AU2005227417B2 (en) Methods of preventing or treating diseases and conditions using complex carbohydrates
Maury Jrogress of fledical Sciente.
CN112358477A (zh) 一种用于治疗胆囊炎的药物及其制备方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP